Skip to main content
ASHP
BCOP Clinical Sessions: Lung Cancer Therapy and Molecular Targets
Targeted therapy in the management of non–small-cell lung cancer is discussed.
Read More
ASHP
Real-World Impact of Prophylactic Pegfilgrastim in Diffuse Large B-Cell Lymphoma (DLBCL) Patients Receiving Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (CHOP) With or Without Rituximab Chemotherapy in Korea
Prophylactic pegfilgrastim was associated with fewer neutropenic events in patients receiving a CHOP-based regimen in DLBCL.
Read More
ASHP
Comparison of Efficacy and Cost-Effectiveness of Filgrastim, tbo-Filgrastim, and Filgrastim-sndz in Patients with Cancer Receiving Myelosuppressive Chemotherapy and Patients with Severe Chronic Neutropenia
An analysis of the efficacy and cost-effectiveness of 3 colony-stimulating factors— filgrastim, tbo-filgrastim, and filgrastim-sndz—is presented.
Read More
ASHP
Personalizing Patient Management and Oral Adherence for the Oncology Patient
The role of the oncology pharmacist in promoting oral adherence for the oncology patient is discussed.
Read More
ASHP
Latest Developments in Short-Acting Granulocyte Colony-Stimulating Factor (G-CSF) Treatment Options: The First FDA-Approved Biosimilar, Zarxio® (filgrastim-sndz)
Biosimilarity between Zarxio and Neupogen is proven through PIONEER study results.
Read More

Results 1 - 5 of 5